American Society of Hematology

Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more

Editas, Beam report updates on sickle cell genetic therapies at this year’s ASH meeting

Plus: How FDA approval trends show biotechs shedding their reliance on pharma

BioCentury’s analysis of the SITC, ASH abstracts highlights progress in bicistronic and tandem CAR Ts

Much stands to be gained from testing cancer drugs first where they’re most likely to succeed

BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo

Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem

As more companies bring IL-18 into their cancer pipelines, they also bring new modalities and approaches to the cytokine’s inhibitory decoy receptor

2023 delivered the second-largest number of FDA new drug approvals ever, yet less innovation in targets, modalities and indications

Execs and investors weigh in on which technologies will yield the biggest gains in innovation in the near term and beyond: BioCentury survey